| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Call to Arms: a Critical Need for Interventions to Limit Pulmonary Toxicity in the Stem Cell Transplantation Patient Population
|
Radhakrishnan, Sabarinath Venniyil
|
|
2015
|
|
1 |
p. 8-17
|
artikel
|
| 2 |
A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
|
Tsang, Mazie
|
|
2017
|
|
1 |
p. 29-38
|
artikel
|
| 3 |
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders
|
Lasho, Terra
|
|
|
|
1 |
p. 35-44
|
artikel
|
| 4 |
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia
|
Österborg, Anders
|
|
2009
|
|
1 |
p. 47-53
|
artikel
|
| 5 |
Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia
|
Hogan, William J.
|
|
|
|
1 |
p. 34-42
|
artikel
|
| 6 |
Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia
|
Pavlů, Jiří
|
|
2012
|
|
1 |
p. 43-51
|
artikel
|
| 7 |
Alternative Donor Transplantation—“Mixing and Matching”: the Role of Combined Cord Blood and Haplo-Identical Donor Transplantation (Haplo-Cord SCT) as a Treatment Strategy for Patients Lacking Standard Donors?
|
Liu, Hongtao
|
|
2015
|
|
1 |
p. 1-7
|
artikel
|
| 8 |
A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine
|
Epperla, Narendranath
|
|
|
|
1 |
p. 19-24
|
artikel
|
| 9 |
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia
|
Venugopal, Sangeetha
|
|
|
|
1 |
p. 89-96
|
artikel
|
| 10 |
A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?
|
Green, Damian J.
|
|
2017
|
|
1 |
p. 61-67
|
artikel
|
| 11 |
AYA Considerations for Aggressive Lymphomas
|
Llaurador, Gabriela
|
|
|
|
1 |
p. 61-71
|
artikel
|
| 12 |
Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions
|
He, Fiona C.
|
|
|
|
1 |
p. 44-52
|
artikel
|
| 13 |
Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions
|
He, Fiona C.
|
|
2018
|
|
1 |
p. 44-52
|
artikel
|
| 14 |
Blinatumomab in Practice
|
Lantz, Jeffrey
|
|
|
|
1 |
p. 1-8
|
artikel
|
| 15 |
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma
|
Shea, Lauren
|
|
|
|
1 |
p. 9-19
|
artikel
|
| 16 |
Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
|
Burger, Jan A.
|
|
2013
|
|
1 |
p. 44-49
|
artikel
|
| 17 |
Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?
|
Thomas, Deborah A.
|
|
2010
|
|
1 |
p. 58-66
|
artikel
|
| 18 |
Can Prognostic Factors Be Used to Direct Therapy in Chronic Lymphocytic Leukemia?
|
Sellner, Leopold
|
|
2011
|
|
1 |
p. 3-12
|
artikel
|
| 19 |
CARs in Chronic Lymphocytic Leukemia – Ready to Drive
|
Hosing, Chitra
|
|
2012
|
|
1 |
p. 60-70
|
artikel
|
| 20 |
Central Nervous System Involvement in Peripheral T Cell Lymphoma
|
Chihara, Dai
|
|
2018
|
|
1 |
p. 1-6
|
artikel
|
| 21 |
Challenges in the Frontline Treatment of Patients With Chronic Lymphocytic Leukemia
|
Lamanna, Nicole
|
|
2010
|
|
1 |
p. 45-51
|
artikel
|
| 22 |
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents
|
Maly, Joseph
|
|
2016
|
|
1 |
p. 52-60
|
artikel
|
| 23 |
Clinical Studies in Hematologic Microtransplantation
|
David, Kevin A.
|
|
2017
|
|
1 |
p. 51-60
|
artikel
|
| 24 |
Clostridium difficile: Deleterious Impact on Hematopoietic Stem Cell Transplantation
|
Callejas-Díaz, Alejandro
|
|
2014
|
|
1 |
p. 85-90
|
artikel
|
| 25 |
CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries
|
Matsuzaki, Mika
|
|
|
|
1 |
p. 1-7
|
artikel
|
| 26 |
Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia
|
Mesa, Ruben A.
|
|
|
|
1 |
p. 25-33
|
artikel
|
| 27 |
Correction to: Strategies for Predicting Response to Checkpoint Inhibitors
|
Zappasodi, Roberta
|
|
2018
|
|
1 |
p. 62
|
artikel
|
| 28 |
Current Approaches to Transplantation for FLT3-ITD AML
|
Hunter, Bradley D.
|
|
|
|
1 |
p. 1-8
|
artikel
|
| 29 |
Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
|
Kothari, Shalin
|
|
2019
|
|
1 |
p. 39-46
|
artikel
|
| 30 |
Disordered Epigenetic Regulation in the Pathophysiology of Myeloproliferative Neoplasms
|
Zhang, Su-Jiang
|
|
2011
|
|
1 |
p. 34-42
|
artikel
|
| 31 |
Do we know more about essential thrombocythemia because of JAK2V617F?
|
Harrison, Claire
|
|
2009
|
|
1 |
p. 25-32
|
artikel
|
| 32 |
Driving CAR-Based T-Cell Therapy to Success
|
Jena, Bipulendu
|
|
2014
|
|
1 |
p. 50-56
|
artikel
|
| 33 |
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
|
Othman, Tamer
|
|
|
|
1 |
p. 1-7
|
artikel
|
| 34 |
Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?
|
Varghese, Abraham M.
|
|
2009
|
|
1 |
p. 35-44
|
artikel
|
| 35 |
Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting
|
Bachow, Spencer H.
|
|
2016
|
|
1 |
p. 61-70
|
artikel
|
| 36 |
Ex Vivo Expansion or Manipulation of Stem Cells to Improve Outcome of Umbilical Cord Blood Transplantation
|
Horwitz, Mitchell E.
|
|
2015
|
|
1 |
p. 12-18
|
artikel
|
| 37 |
Farnesyltransferase inhibitors in myelodysplastic syndrome
|
Feldman, E. J.
|
|
|
|
1 |
p. 20-24
|
artikel
|
| 38 |
Future Therapies for the Myeloproliferative Neoplasms
|
Scherber, Robyn
|
|
2010
|
|
1 |
p. 22-27
|
artikel
|
| 39 |
Genetic Events Other than BCR-ABL1
|
Neviani, Paolo
|
|
2014
|
|
1 |
p. 24-32
|
artikel
|
| 40 |
Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?
|
Shaw, Bronwen E.
|
|
2019
|
|
1 |
p. 22-30
|
artikel
|
| 41 |
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia
|
Macias-Perez, Ines M.
|
|
2012
|
|
1 |
p. 22-27
|
artikel
|
| 42 |
High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies
|
Sharma, Sujata
|
|
|
|
1 |
p. 112-116
|
artikel
|
| 43 |
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents
|
Nabrinsky, Edward
|
|
|
|
1 |
p. 8-18
|
artikel
|
| 44 |
High-Risk Myelodysplastic Syndromes: Chemotherapy, Transplantation, and Beyond
|
Gergis, Usama
|
|
2010
|
|
1 |
p. 1-8
|
artikel
|
| 45 |
Hypomethylating Agents as a Therapy for AML
|
Gardin, Claude
|
|
2017
|
|
1 |
p. 1-10
|
artikel
|
| 46 |
Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
|
Brown, Jennifer R.
|
|
2013
|
|
1 |
p. 1-6
|
artikel
|
| 47 |
Identification and Utilization of Donor and Recipient Genetic Variants to Predict Survival After HCT: Are We Ready for Primetime?
|
Sucheston-Campbell, Lara E.
|
|
2015
|
|
1 |
p. 45-58
|
artikel
|
| 48 |
Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant
|
Merryman, Reid W.
|
|
2017
|
|
1 |
p. 44-50
|
artikel
|
| 49 |
Immune Reconstitution in Chronic Lymphocytic Leukemia
|
Riches, John C.
|
|
2011
|
|
1 |
p. 13-20
|
artikel
|
| 50 |
Immune Reconstitution in Chronic Lymphocytic Leukemia
|
Riches, John C.
|
|
|
|
1 |
p. 13-20
|
artikel
|
| 51 |
Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy
|
Tse, Eric
|
|
2018
|
|
1 |
p. 37-43
|
artikel
|
| 52 |
Immunology and Immunotherapy of Chronic Myeloid Leukemia
|
Ilander, Mette
|
|
2014
|
|
1 |
p. 17-23
|
artikel
|
| 53 |
Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
|
Htut, Myo
|
|
2019
|
|
1 |
p. 1-10
|
artikel
|
| 54 |
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
|
Doraiswamy, Anupama
|
|
|
|
1 |
p. 72-81
|
artikel
|
| 55 |
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
|
Freeman, Ciara L.
|
|
2016
|
|
1 |
p. 29-36
|
artikel
|
| 56 |
Impact of the Affordable Care Act on Stem Cell Transplantation
|
Farnia, Stephanie
|
|
2014
|
|
1 |
p. 66-72
|
artikel
|
| 57 |
Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy
|
Ittershagen, Stacie
|
|
2019
|
|
1 |
p. 47-55
|
artikel
|
| 58 |
Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia
|
Burger, Jan A.
|
|
2011
|
|
1 |
p. 26-33
|
artikel
|
| 59 |
Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?
|
Broccoli, Alessandro
|
|
|
|
1 |
p. 82-88
|
artikel
|
| 60 |
Iron overload in patients with myelodysplastic syndromes
|
Jensen, Peter-D.
|
|
|
|
1 |
p. 13-21
|
artikel
|
| 61 |
JAK2 Mutation and Thrombosis in the Myeloproliferative Neoplasms
|
Vannucchi, Alessandro M.
|
|
2010
|
|
1 |
p. 22-28
|
artikel
|
| 62 |
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra
|
Montanari, Francesca
|
|
|
|
1 |
p. 52-60
|
artikel
|
| 63 |
Lenalidomide Alone and in Combination for Chronic Lymphocytic Leukemia
|
Chen, Christine I.
|
|
2012
|
|
1 |
p. 7-13
|
artikel
|
| 64 |
Lenalidomide in Myelodysplastic Syndromes: An Erythropoiesis-Stimulating Agent or More?
|
Komrokji, Rami S.
|
|
2009
|
|
1 |
p. 9-14
|
artikel
|
| 65 |
Lessons from ALL-REZ BFM 90: Therapy for Childhood Leukemia Based on Timing and Site of Relapse
|
Rytting, Michael E.
|
|
2012
|
|
1 |
p. 1-2
|
artikel
|
| 66 |
Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings
|
Ruiz-Argüelles, Guillermo J.
|
|
|
|
1 |
p. 40-44
|
artikel
|
| 67 |
Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
|
Burchert, Andreas
|
|
2014
|
|
1 |
p. 9-16
|
artikel
|
| 68 |
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia
|
McNeer, Jennifer L.
|
|
|
|
1 |
p. 1-14
|
artikel
|
| 69 |
Management of myelodysplastic syndromes in the geriatric patient
|
Ritchie, Ellen K.
|
|
2009
|
|
1 |
p. 3-9
|
artikel
|
| 70 |
Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice
|
Barosi, Giovanni
|
|
2012
|
|
1 |
p. 50-56
|
artikel
|
| 71 |
Management of Refractory Acute Myeloid Leukemia: Re-induction Therapy or Straight to Transplantation?
|
Feldman, E. J.
|
|
2011
|
|
1 |
p. 74-77
|
artikel
|
| 72 |
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies
|
Rainone, Michael
|
|
|
|
1 |
p. 39-45
|
artikel
|
| 73 |
Management of the New Patient with CML in Chronic Phase
|
Marin, David
|
|
2013
|
|
1 |
p. 37-42
|
artikel
|
| 74 |
Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
|
Gustafson, Dakota
|
|
|
|
1 |
p. 20-30
|
artikel
|
| 75 |
Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia
|
Douvas, Michael G.
|
|
|
|
1 |
p. 15-24
|
artikel
|
| 76 |
Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation
|
Andermann, Tessa M.
|
|
2016
|
|
1 |
p. 19-28
|
artikel
|
| 77 |
Mixed myeloproliferative and myelodysplastic disorders
|
Emanuel, Peter D.
|
|
|
|
1 |
p. 9-12
|
artikel
|
| 78 |
Molecular Monitoring
|
Soverini, Simona
|
|
2014
|
|
1 |
p. 1-8
|
artikel
|
| 79 |
Monoclonal B Cell Lymphocytosis—What Does It Really Mean?
|
Rawstron, Andy C.
|
|
2013
|
|
1 |
p. 52-59
|
artikel
|
| 80 |
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift
|
Wall, Sarah A.
|
|
|
|
1 |
p. 31-38
|
artikel
|
| 81 |
Myelodysplastic syndrome: An update on diagnosis and therapy
|
Koppel, Ahrin
|
|
2009
|
|
1 |
p. 10-16
|
artikel
|
| 82 |
Myelofibrosis—When Do We Select Transplantation or Non-transplantation Therapeutic Options?
|
Viswabandya, Auro
|
|
2015
|
|
1 |
p. 6-11
|
artikel
|
| 83 |
Myeloproliferative Neoplasms with Monocytosis
|
Morsia, Erika
|
|
|
|
1 |
p. 46-51
|
artikel
|
| 84 |
New Agents in Chronic Lymphocytic Leukemia
|
Lin, Thomas S.
|
|
2010
|
|
1 |
p. 29-34
|
artikel
|
| 85 |
New and old prognostic factors in polycythemia vera
|
Passamonti, Francesco
|
|
2009
|
|
1 |
p. 19-24
|
artikel
|
| 86 |
New Drugs for the Treatment of Myelofibrosis
|
Mesa, Ruben A.
|
|
2010
|
|
1 |
p. 15-21
|
artikel
|
| 87 |
NK/T Cell Lymphoma: Updates in Therapy
|
Suzuki, Ritsuro
|
|
2018
|
|
1 |
p. 7-12
|
artikel
|
| 88 |
Novel Biomarkers and Molecular Targets in ALL
|
De Sa, Hong
|
|
|
|
1 |
p. 18-34
|
artikel
|
| 89 |
Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia
|
Zanwar, Saurabh
|
|
|
|
1 |
p. 31-43
|
artikel
|
| 90 |
Patient Selection for Allogeneic Hematopoietic Cell Transplantation (HCT): the Evolution of HCT Risk Assessment
|
Muffly, Lori
|
|
2014
|
|
1 |
p. 28-34
|
artikel
|
| 91 |
PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia
|
Chang, Julie E.
|
|
2014
|
|
1 |
p. 33-43
|
artikel
|
| 92 |
Prognostication in Primary Myelofibrosis
|
Cervantes, Francisco
|
|
2011
|
|
1 |
p. 43-49
|
artikel
|
| 93 |
Prognostic Factors for Chronic Lymphocytic Leukemia
|
Chen, Christopher
|
|
2016
|
|
1 |
p. 37-42
|
artikel
|
| 94 |
Prognostic factors in chronic lymphocytic leukemia
|
Kay, Neil E.
|
|
|
|
1 |
p. 49-55
|
artikel
|
| 95 |
Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms—Where Are We Today?
|
Horton, Lucy E.
|
|
2018
|
|
1 |
p. 59-67
|
artikel
|
| 96 |
Richter Syndrome in Chronic Lymphocytic Leukemia
|
Vitale, Candida
|
|
2016
|
|
1 |
p. 43-51
|
artikel
|
| 97 |
Role of Epigenetics in Chronic Myeloid Leukemia
|
Machova Polakova, Katerina
|
|
2013
|
|
1 |
p. 28-36
|
artikel
|
| 98 |
Role of TET2 Mutations in Myeloproliferative Neoplasms
|
Pronier, Elodie
|
|
2011
|
|
1 |
p. 57-64
|
artikel
|
| 99 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options
|
Richardson, Daniel R.
|
|
|
|
1 |
p. 97-111
|
artikel
|
| 100 |
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies
|
Al-Juhaishi, Taha
|
|
|
|
1 |
p. 32-39
|
artikel
|
| 101 |
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
|
Holstein, Sarah A.
|
|
2019
|
|
1 |
p. 31-38
|
artikel
|
| 102 |
Should Patients with Low-Risk Myelodysplastic Syndrome be Treated Earlier in the Course of Their Disease?
|
Feldman, Eric J.
|
|
2010
|
|
1 |
p. 1-2
|
artikel
|
| 103 |
Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
|
Ahmed, Wesam
|
|
2013
|
|
1 |
p. 71-80
|
artikel
|
| 104 |
Special Issues in Myeloproliferative Neoplasms
|
Barbui, Tiziano
|
|
2010
|
|
1 |
p. 28-35
|
artikel
|
| 105 |
Stem cell transplantation for myelodysplastic syndromes: The lure of a cure
|
Shore, Tsiporah
|
|
|
|
1 |
p. 3-8
|
artikel
|
| 106 |
Survival Advantage in CLL with Frontline FCR Therapy
|
O’Brien, Susan
|
|
2010
|
|
1 |
p. 3-4
|
artikel
|
| 107 |
Survivorship After Allogeneic Transplantation—Management Recommendations for the Primary Care Provider
|
Tichelli, André
|
|
2015
|
|
1 |
p. 35-44
|
artikel
|
| 108 |
Targeted Therapies for Follicular Lymphoma
|
Girard, Jennifer
|
|
|
|
1 |
p. 25-31
|
artikel
|
| 109 |
Targeted Therapy in Chronic Lymphocytic Leukemia (CLL)
|
Pettijohn, Erin M.
|
|
2017
|
|
1 |
p. 20-28
|
artikel
|
| 110 |
Targeting Chronic Myeloid Leukemia Stem Cells
|
Kinstrie, Ross
|
|
2012
|
|
1 |
p. 14-21
|
artikel
|
| 111 |
T Cell-Depleted and T Cell-Replete HLA-Haploidentical Stem Cell Transplantation for Non-malignant Disorders
|
Bertaina, Alice
|
|
2017
|
|
1 |
p. 68-78
|
artikel
|
| 112 |
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
|
Lampson, Benjamin L.
|
|
2017
|
|
1 |
p. 11-19
|
artikel
|
| 113 |
The Difficulties of Informed Consent in Stem Cell Transplant
|
Cook, Rachel J.
|
|
2016
|
|
1 |
p. 1-5
|
artikel
|
| 114 |
The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas
|
Horwitz, Steven M.
|
|
2010
|
|
1 |
p. 67-72
|
artikel
|
| 115 |
The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders
|
Crombie, Jennifer
|
|
2019
|
|
1 |
p. 11-21
|
artikel
|
| 116 |
The Evolving Role of Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia
|
Davids, Matthew S.
|
|
2015
|
|
1 |
p. 18-27
|
artikel
|
| 117 |
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)
|
Ma, Helen
|
|
|
|
1 |
p. 13-24
|
artikel
|
| 118 |
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)
|
Ma, Helen
|
|
2018
|
|
1 |
p. 13-24
|
artikel
|
| 119 |
Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions
|
Navada, Shyamala C.
|
|
2010
|
|
1 |
p. 5-12
|
artikel
|
| 120 |
The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings
|
Rodrigues, Celso Arrais
|
|
2010
|
|
1 |
p. 47-57
|
artikel
|
| 121 |
The Search for Better Prognostic Models in Myelodysplastic Syndromes
|
Santos, Fabio P. S.
|
|
2010
|
|
1 |
p. 13-21
|
artikel
|
| 122 |
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis
|
Thiele, Juergen
|
|
2009
|
|
1 |
p. 33-40
|
artikel
|
| 123 |
Thinking Out of the Box—New Approaches to Controlling GVHD
|
Baron, Frédéric
|
|
2014
|
|
1 |
p. 73-84
|
artikel
|
| 124 |
Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?
|
Kundranda, Madappa N.
|
|
2011
|
|
1 |
p. 78-86
|
artikel
|
| 125 |
Transplantation in chronic lymphocytic leukemia
|
Le Dieu, Rifca
|
|
|
|
1 |
p. 56-63
|
artikel
|
| 126 |
Treatment-Free Remission in CML: the US Perspective
|
Guru Murthy, Guru Subramanian
|
|
2019
|
|
1 |
p. 56-61
|
artikel
|
| 127 |
Treatment of Older Patients with Chronic Lymphocytic Leukemia
|
Lamanna, Nicole
|
|
2012
|
|
1 |
p. 21-25
|
artikel
|
| 128 |
Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT)
|
Atallah, Ehab
|
|
2014
|
|
1 |
p. 57-65
|
artikel
|
| 129 |
Twitter Use in the Hematopoietic Cell Transplantation Community
|
Patel, Sagar S.
|
|
2018
|
|
1 |
p. 53-58
|
artikel
|
| 130 |
Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|
Alhajahjeh, Abdulrahman
|
|
|
|
1 |
p. 9-17
|
artikel
|
| 131 |
Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate
|
Silver, Richard T.
|
|
|
|
1 |
p. 43-46
|
artikel
|
| 132 |
Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification
|
Siaghani, Parwiz J.
|
|
|
|
1 |
p. 25-36
|
artikel
|
| 133 |
Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification
|
Siaghani, Parwiz J.
|
|
2018
|
|
1 |
p. 25-36
|
artikel
|
| 134 |
Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons
|
Elter, Thomas
|
|
2009
|
|
1 |
p. 43-46
|
artikel
|
| 135 |
Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities
|
Lloyd, Jennifer
|
|
|
|
1 |
p. 25-30
|
artikel
|
| 136 |
Web alert
|
|
|
|
|
1 |
p. 2-6
|
artikel
|
| 137 |
What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
|
Sellner, L.
|
|
2012
|
|
1 |
p. 81-90
|
artikel
|
| 138 |
What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?
|
Jurcic, Joseph G.
|
|
2011
|
|
1 |
p. 65-73
|
artikel
|
| 139 |
What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?
|
Badoux, Xavier C.
|
|
2010
|
|
1 |
p. 36-46
|
artikel
|
| 140 |
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma
|
Nastoupil, Loretta J.
|
|
|
|
1 |
p. 45-51
|
artikel
|
| 141 |
Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?
|
Dreger, Peter
|
|
2015
|
|
1 |
p. 59-64
|
artikel
|
| 142 |
10 Years of Preparedness by the Radiation Injury Treatment Network
|
Case, Cullen
|
|
2017
|
|
1 |
p. 39-43
|
artikel
|
Tijdschrift beschrijving